Jiangshui-derived Lactobacillus plantarum GR-4 enhances the therapeutic efficacy of PD-1/PD-L1 inhibitors against gastric cancer
5 affiliations
- 1Department of Oncology, The Second Hospital & Clinical Medical School, Lanzhou University
- 2Departments of Orthopedics, The Second Hospital & Clinical Medical School, Lanzhou University
- 3Centre for Grassland Microbiome, State Key Laboratory of Herbage Improvement and Grassland Agro-ecosystems, College of Pastoral Agricultural Science and Technology, Lanzhou University
- 4Ministry of Education Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University
- 5The Second Hospital & Clinical Medical School, Lanzhou University
Abstract
Objective: To investigate whether the Jiangshui-derived probiotic Lactobacillus plantarum GR-4 can enhance gastric cancer sensitivity to PD-1 inhibitors and reshape the tumor immune microenvironment.
Methods: A mouse gastric cancer model was established. Mice received oral GR-4 monotherapy, PD-1 blocking antibody monotherapy, or combined GR-4 and PD-1 antibody treatment. In vivo antitumor efficacy was evaluated by measuring tumor weight. We assessed CD8 ⁺ T-cell infiltration, cytokines related to T-cell activation and differentiation, and the expression of the activation marker CD69 on CD3 ⁺ /CD8 ⁺ T cells within tumor tissues. 16S rRNA sequencing of gut microbiota and fecal metabolomic analysis were performed to explore the regulatory effects of GR-4 on gut microbiota composition and metabolic profiles. In vitro , human gastric cancer BGC-823 cells were treated with GR-4 combined with PD-1 intervention, and transcriptome sequencing was applied to further validate the underlying molecular regulatory mechanisms.
Results: In vivo results demonstrated that combined GR-4 and PD-1 antibody treatment exerted prominent synergistic antitumor activity, effectively suppressing tumor growth while markedly mitigating PD-1-associated body weight loss (p < 0.01). Further assays revealed that GR-4 synergistically elevated tumor-infiltrating CD3 ⁺ /CD8 ⁺ T-cell levels and upregulated CD69 expression on these cells, thereby remodelling the tumor immune microenvironment. Additionally, GR-4, whether administered alone or combined with PD-1 antibody, optimized gut microbiota structure, increased the abundance of probiotic genera including Ligilactobacillus and Bacteroides , reversed intestinal metabolic disturbances, and raised the levels of short-chain fatty-acid-related metabolites such as ethoxyacetic acid and 2,5-dihydroxybenzoic acid. Transcriptomic sequencing showed significant enrichment of the PD-1 checkpoint pathway in the GR-4 group versus Ctrl (p=0.01), whereas no significant enrichment was observed between the PD-1 inhibitor group and GR-4/PD-1 inhibitor group (p=0.14).
Conclusion: This study is the first to confirm that Lactobacillus plantarum GR-4 synergizes with PD-1 inhibitors to restrain gastric cancer progression via T-cell activation and elevated intratumoral T-cell infiltration. These findings provide novel theoretical evidence and a potential combinatorial immunotherapeutic strategy for gastric cancer.
Related
- Chickpea flour (Cicer arietinum L) improves viability of potentially probiotics Lactobacillus plantarum S180.7 and Lactobacillus plantarum SBR64.7 in milk-based formulations
- A multi-omics characterization of the gut microbiota of weaned piglets in response to Lactobacillus plantarum supplementation.
- Anti-inflammatory effects of vitamin K2 and Lactobacillus plantarum in a mouse model of colorectal cancer
- Co-inoculation with Lactiplantibacillus plantarum and Bacillus amyloliquefaciens enhances the fermentation quality and in vitro ruminal digestibility of whole-plant millet silage
- Widening the BRCAness therapeutic window for its synthetic lethality effects with PARP inhibitors
BibTeX
@article{wang2026jiangshuiderived,
title = {{Jiangshui-derived Lactobacillus plantarum GR-4 enhances the therapeutic efficacy of PD-1/PD-L1 inhibitors against gastric cancer}},
author = {Na Wang and Kai Wang and Huawen Han and Jingwen Fan and Feixue Song and Hao Chen and Xiangkai Li},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1987320},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1987320/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Jiangshui-derived Lactobacillus plantarum GR-4 enhances the therapeutic efficacy of PD-1/PD-L1 inhibitors against gastric cancer
AU - Na Wang
AU - Kai Wang
AU - Huawen Han
AU - Jingwen Fan
AU - Feixue Song
AU - Hao Chen
AU - Xiangkai Li
PY - 2026
DA - 2026/10/29
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1987320
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1987320/full
AB - Objective: To investigate whether the Jiangshui-derived probiotic Lactobacillus plantarum GR-4 can enhance gastric cancer sensitivity to PD-1 inhibitors and reshape the tumor immune microenvironment. Methods: A mouse gastric cancer model was established. Mice received oral GR-4 monotherapy, PD-1 blocking antibody monotherapy, or combined GR-4 and PD-1 antibody treatment. In vivo antitumor efficacy was evaluated by measuring tumor weight. We assessed CD8 ⁺ T-cell infiltration, cytokines related to T-cell activation and differentiation, and the expression of the activation marker CD69 on CD3 ⁺ /CD8 ⁺ T cells within tumor tissues. 16S rRNA sequencing of gut microbiota and fecal metabolomic analysis were performed to explore the regulatory effects of GR-4 on gut microbiota composition and metabolic profiles. In vitro , human gastric cancer BGC-823 cells were treated with GR-4 combined with PD-1 intervention, and transcriptome sequencing was applied to further validate the underlying molecular regulatory mechanisms. Results: In vivo results demonstrated that combined GR-4 and PD-1 antibody treatment exerted prominent synergistic antitumor activity, effectively suppressing tumor growth while markedly mitigating PD-1-associated body weight loss (p < 0.01). Further assays revealed that GR-4 synergistically elevated tumor-infiltrating CD3 ⁺ /CD8 ⁺ T-cell levels and upregulated CD69 expression on these cells, thereby remodelling the tumor immune microenvironment. Additionally, GR-4, whether administered alone or combined with PD-1 antibody, optimized gut microbiota structure, increased the abundance of probiotic genera including Ligilactobacillus and Bacteroides , reversed intestinal metabolic disturbances, and raised the levels of short-chain fatty-acid-related metabolites such as ethoxyacetic acid and 2,5-dihydroxybenzoic acid. Transcriptomic sequencing showed significant enrichment of the PD-1 checkpoint pathway in the GR-4 group versus Ctrl (p=0.01), whereas no significant enrichment was observed between the PD-1 inhibitor group and GR-4/PD-1 inhibitor group (p=0.14). Conclusion: This study is the first to confirm that Lactobacillus plantarum GR-4 synergizes with PD-1 inhibitors to restrain gastric cancer progression via T-cell activation and elevated intratumoral T-cell infiltration. These findings provide novel theoretical evidence and a potential combinatorial immunotherapeutic strategy for gastric cancer.
SN - 1664-3224
ER -